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ity must be invoked to explain the observed level of albumin-Glomerular permselectivity in early stages of overt diabetic
uria, however.nephropathy.
Background. Impairment of glomerular size selectivity has
been demonstrated by the dextran-sieving technique in nephro-
pathic diabetics with heavy, but not mild proteinuria. The pur-
The onset of diabetic nephropathy (DN) is heralded bypose of the present study was to determine whether such a
the development of pathological levels of albuminuria.barrier defect could be demonstrated with mild proteinuria by
substituting Ficoll 70, a polysucrose, for dextran as a probe of Typically, such albuminuria is initially of modest propor-
the filtration barrier. tions, and the mechanism responsible for the underlying
Methods. Differential solute clearances were performed in defect in glomerular barrier function has been difficult12 individuals with early diabetic nephropathy on two occa-
to clarify. Measurable concentrations of albumin of ap-sions: after 60 days of treatment with losartan 50 mg daily or
proximately 1 mg/dL have been consistently observeda placebo. An uncharged preparation of nonreabsorbable Fi-
coll 70 was infused along with inulin. Fractional clearance (u) in the Bowman’s space fluid of healthy animals, indicat-
of Ficoll of discrete size was determined after separating mole- ing that the normal glomerular capillary wall is not com-
cules in urine and plasma in narrow 2 A˚ fractions over a 20 to
pletely impermeable to albumin [1–3]. Furthermore, some60 A˚ radius interval by size exclusion high-performance liquid
90% of normally filtered albumin has been shown tochromatography (HPLC). A hydrodynamic theory of hindered
ficoll transport through water-filled pores was used to charac- undergo proximal tubular reabsorption, with the result
terize the pore size distribution of the glomerular barrier. that measured albuminuria in normal rats approximates
Results. The u for Ficoll molecules with radii .50 A˚ was only 10% of the corresponding filtered load. Tucker,selectively enhanced in placebo-treated diabetic nephropathy
Rasch, and Blantz have recently examined albuminversus corresponding u in healthy control subjects (N 5 12).
clearance and renal tissue accumulation of filtered albu-Computations revealed a lower distribution of glomerular
pores that was unaltered in nephropathic diabetics. However, min to study the genesis of albuminuria associated with
an upper distribution of large, shunt-like pores was more prom- streptozotocin-induced diabetes in rats [4]. They found
inent, exceeding healthy controls by one order of magnitude the filtered albumin load to be elevated 50 to 70 daysin diabetic nephropathy (P 5 0.01). A trend to lower u for
after induction of diabetes. In addition, tubular reabsorp-Ficoll in the 56 to 60 A˚ radius range during losartan therapy
tion of albumin was severely depressed, leading themis computed to have lowered the fraction of shunted filtrate
by 26 to 44%, depending on whether glomerular pressure de- to conclude that the enhanced albuminuria that they
clined. The corresponding reduction in u for endogenous albu- observed (120 mg/min) was partly glomerular and partly
min, IgG, and IgG4 was by 19 to 23% (P , 0.05). tubular in origin [4].Conclusion. Our findings suggest that shunt-like defects,
The uncertain contribution of impaired tubule re-partially reversible by angiotensin II blockade, are present
absorption to proteinuria has made the technique ofearly in the course of diabetic nephropathy. We estimate that
such defects can account for immunoglobulinuria in this disor- differential protein clearances in subjects with early DN
der. Additional impairment of either charge- or shape-selectiv- difficult to interpret. The clearance of albumin (Stokes-
Einstein radius 5 36 A˚, isoelectric point 5 4 to 5) has
been compared with that of immunoglobulin G (IgG;Key words: filtration barrier defect, nephropathic diabetes, proteinuria,
ficol, albuminuria, immunoglobulinuria. radius 5 55 A˚, isoelectric point 5 4 to 10). A selective
increase in the former has been interpreted to indicate
Received for publication February 9, 2000
preservation of size selectivity [5]. Given the unknownand in revised form May 30, 2000
Accepted for publication June 5, 2000 contributions of tubular reabsorption to the urinary clear-
ances of both albumin and IgG, however, this inferenceÓ 2000 by the International Society of Nephrology
2129
Andersen et al: Glomerular permselectivity2130
is open to question. A second finding early in the course uncharged Ficoll 70 as the test macromolecule to probe
the glomerular capillary wall. Whereas dextrans behaveof DN is that the urinary clearance of the most anionic
species of either albumin or IgG has been shown to be as random coils in solution, they become uncoiled under
shear. As a consequence, their transport during transglo-elevated relative to that of less anionic or cationic species
of the same protein [5–9]. This finding has been interpre- merular permeation is facilitated, thereby leading to an
overestimate of the effective pore radius presented toted by several groups of workers to indicate impairment
of barrier charge-selectivity. Neutralization of the nega- spherical proteins [19, 20]. In contrast, Ficoll 70 behaves
as a rigid sphere during transglomerular permeationtively charged electrostatic barrier within the glomerular
capillary wall, however, should lead only to equalization [21, 22]. Accordingly, it is more restricted by the glomer-
ular capillary wall than a dextran of equivalent chromato-of sieving coefficients for anionic and cationic species of
a given protein [10]. A more likely explanation for the graphic radius and more closely approximates the spheri-
cal molecule envisaged in pore theory models. It isobserved reversal of charge selectivity of proteinuria is
that tubular reabsorption of filtered proteins that are noteworthy therefore, that using Ficoll, Remuzzi et al
were able to demonstrate selectively enhanced passagecationic is facilitated by enhanced binding to the nega-
tively charged brush border, thereby favoring clearance of Ficoll of .50 A˚ radius and hence a size defect in
the glomerular capillary walls of streptozotocin-inducedof proteins that are anionic into the final urine [11, 12].
We have attempted to determine whether impaired diabetic rats with only modest albuminuria [18]. In the
present study, we have attempted to replicate this findingbarrier size-selectivity contributes to low-level albumin-
uria in early DN. To circumvent the confounding varia- in nephropathic humans with low-grade albuminuria, so
as to determine unambiguously whether impairment oftions in protein-specific and charge-dependent tubular
reabsorption in this setting, we employed an exogenous barrier size selectivity is associated with an early stage
of overt DN in humans. To further elucidate any relation-preparation of the uncharged polymer dextran 40 as a
macromolecular probe of the glomerular barrier. Be- ship between impaired size selectivity and the magnitude
of albuminuria, we attempted to reduce the latter bycause dextran is neither reabsorbed nor secreted by the
tubule, the fractional clearance of a given dextran is the blockade of angiotensin II type I (AT1) receptors and
compared glomerular sieving characteristics toward Fi-same as its Bowman’s space fluid/plasma concentration
ratio, that is, its sieving coefficient (u). We first showed coll at both the higher and lower levels of albuminuria.
that in patients with DN and nephrotic-range protein-
uria, there was selectively enhanced passage of large,
METHODS
nearly impermeant dextrans of .50 A˚ radius [9, 13–15].
Experimental subjectsThis finding has now been confirmed by others and sug-
gests the emergence of a small number of enlarged, pro- Twelve patients undergoing management of type I
diabetes at the Steno Diabetes Center in Gentofte (Den-tein-permeable pores in the glomerular capillary wall
[16, 17]. A comparable defect in size selectivity has been mark) were recruited for study. Each gave informed con-
sent to differential solute clearances and a trial of losartandifficult to demonstrate unequivocally in patients with
DN and lower grades of albuminuria, however. In sub- therapy, using a protocol that had been approved pre-
viously by the local ethical committee of the Steno Dia-jects with subnephrotic levels of proteinuria in particular,
we were unable to demonstrate a significant increase in betes Center. The basis for their selection was the diag-
nosis of early but overt DN. DN was diagnosed clinicallyu even for the largest dextrans in our infusate [9, 14, 15].
Thus, at least in human DN, it remains difficult to assess on the basis of an albumin excretion rate .300 mg/24
hours, diabetic retinopathy, and the absence of clinicalthe relative contributions of either an increase in albumin
filtration or a reduction in albumin reabsorption to low- and laboratory evidence of other nondiabetic renal dis-
ease. It was judged to be early on the basis of normallevel albuminuria. Moreover, even granting that in-
creased albumin filtration is probable, at present there levels of serum creatinine (that is, ,1.4 mg/dL in males
and ,1.2 mg/dL in females) and normotension (bloodis no way to decide from the available evidence whether
it is a consequence of an impairment of barrier size or pressure ,150/,90 mm Hg in the absence of current
or prior treatment with antihypertensive agents). Theycharge or shape selectivity, or a combination of all three.
Less ambiguous evidence for an association between included seven males and five females. The mean 6 SEM
age was 40 6 3 years, and the duration of diabetes wasimpairment of size selectivity and low grade albuminuria
has recently been provided by Remuzzi et al in a strepto- 30 6 3 years. The daily dose of insulin averaged 42 6 6
units. Concentrations of glycosylated hemoglobin A1C atzotocin-induced rat model of early DN. The model was
an analogue of early nephropathy in humans as judged the time of selection were measured by high-performance
liquid chromatography (HPLC) and averaged 8.0 6by the presence of a normal glomerular filtration rate
(GFR), a minor, twofold increase in proteinuria, and a 0.3% (normal range 4.6 to 6.1%). Twelve healthy volun-
teers aged 27 6 2 years, of whom seven were males,low prevalence of glomerulosclerosis [18]. They used
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sampled for renin and angiotensin II (Ang II) levels in
plasma. Differential solute clearances were next per-
formed during water diuresis. Each subject was infused
with a bolus of inulin (50 mg/kg) and para-aminohippur-
ate (PAH; 12 mg/kg), followed by a continuous infusion
to maintain a constant plasma concentration of each
marker. After a 60-minute equilibration period, a bolus
of one (1.0) mCi of tritiated Ficoll 70 (3H-Ficoll) was
given, and then four carefully timed urine collections
were made at 20-minute intervals. Plasma was sampled
Fig. 1. Design of the crossover study. Subjects were randomized to 60 to bracket each collection. The average urinary clearance
days of either placebo (protocol 1) or losartan therapy (protocol 2). of inulin was equated with the GFR. The rate of renalThis was followed by a 15-day washout period after which each subject
plasma flow was derived by dividing the correspondingcrossed over to 60 days of the remaining therapy not given on the first
occasion. *Days on which differential solute clearances were performed. PAH clearance by an estimated PAH extraction ratio
of 0.9 in the control group and 0.8 for GFR $80 mL/min
or 0.7 for GFR ,80 mL/min in the DN group [23]. Frac-
tional clearances (u) of endogenous proteins and Ficollprovided control values for the glomerular functional
molecules of descrete radius were calculated for the thirdquantities of interest. All denied a history of renal dis-
clearance period by dividing the clearance of the forego-ease, hypertension, and diabetes, and each was found not
ing macromolecules by that of inulin [21].to have pathological proteinuria, as judged by a negative
dipstick test. Each gave consent to the performance of Preparation of tritiated Ficoll 70 for infusion
differential solute clearance using a protocol that had
Unlabeled Ficoll 70 was purchased from Pharmaciabeen approved by the Institutional Review Board at
LKB (Uppsala, Sweden) and transferred to the ResearchStanford University.
Products Division of New England Nuclear Corp. (Bos-
ton, MA, USA) for tritiation. Separate lots of Ficoll eachProtocol
weighing 1000 mg were dissolved in 6 mL water. UsingVolunteer controls were admitted to the General Clin-
200 mg of 5% Rh/Al2O3 as a catalyst, 50 Ci of tritiumical Research Center at Stanford University Hospital.
gas were added to the solution, and the mixture wasThey underwent a study of glomerular function by the
stirred for 48 hours at 258C. After removal of excess
differential solute clearance technique on a single occa- gaseous and labile tritium, the preparation was returned
sion. The nephropathic subjects with type I diabetes were to the renal research laboratory at Stanford (CA, USA).
admitted to the Clinical Research Center at the Steno One milliliter aliquots of the product were passed over
Diabetes Center for the performance of differential sol- a desalting column (Bio-Gel P-6 DG; Bio-Rad Labora-
ute clearances on two occasions, each separated by an tories, Hercules, CA, USA). We disposed of the fraction
interval of 75 days. Each nephropathic subject under- containing unbound tritium, which accounted for be-
went a trial of losartan with a crossover design (Fig. 1). tween 80 and 96% of the total radioactivity in the prepa-
Subjects were randomized to 60 days of treatment with ration. The fractions containing 3H-Ficoll 70 were pooled
either losartan 50 mg or a look-alike placebo once daily and filtered through a 0.22 mm Millex-GV filter (Milli-
(first treatment). After a 15-day washout period without pore, Bradford, MA, USA). After the filtrate was tested
therapy, each subject was then crossed over to 60 days and found to be sterile and free of pyrogens, it was
of the remaining therapy not given on the first occasion divided into aliquots in vials each containing 1.0 mCi of
(Fig. 1). Differential solute clearances were performed 3H-Ficoll. It was then transferred to the Steno Diabetes
on the 60th day of treatment with either the losartan or Center (Gentofte, Denmark), where it was stored at 48C
the placebo. Blood pressure was monitored automati- until the day of infusion. The 3H activity in each dose
cally with an ambulatory Takeda TM device (A & D, ranged from 10 to 25 mCi/mg Ficoll, thus necessitating
Tokyo, Japan) throughout a 24-hour period spanning infusion of 27 to 67 mg of Ficoll to deliver 1.0 mCi of
the time during which the clearances were determined. tritium to each study subject. The molecules of Ficoll 70
Determinations were made at 15-minute intervals be- in infusate spanned a radius range of 10 to 90 A˚ with
tween 7 a.m. and 11 p.m. and at 30-minute intervals the peak radius at 30 A˚. The corresponding interval and
between 11 p.m. and 7 a.m. The mean hourly values peak of radii for inulin were 10 to 22 A˚ and 18 A˚,
were averaged to calculate a 24-hour blood pressure. respectively.
An identical protocol was used for each sequential
Laboratory determinationsstudy. Urines were collected at 24-hour intervals over
three days for determination of the excretion rates of After completion of clearance studies in the nephro-
pathic subjects with diabetes, samples were stored aturinary proteins, creatinine, and sodium. Blood was then
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2708C and transferred in batches to the renal research The reproducibility of the urine-to-serum concentration
ratios for Ficoll at each of the 22 size intervals was exam-laboratories at Stanford University. An autoanalyzer
ined. Samples of urine and serum from different patientstechnique was used to assay inulin and PAH concentra-
were pooled, aliquoted, and stored at 2708C. Aliquotstions [23]. An additional determinant of GFR, the on-
were removed from storage and separated by size bycotic pressure of plasma, was determined by membrane
HPLC, and the urine-to-serum concentration ratio forosmometry [24]. Urine samples from the 24-hour collec-
Ficoll was examined on 12 separate occasions. The assaytions and urine and plasma samples from the clearance
coefficients of variation for the concentration ratio overperiods were assayed by enzyme-linked immunosorbent
the entire size interval of Ficoll molecules examinedassay to determine the excretion rate and fractional
ranged between 6 and 10% and is summarized in Table 1.clearances, respectively, of albumin IgG and IgG4 [9, 25].
Renin concentration and Ang II levels in plasma were
Computations based on pore theorydetermined only in the diabetic group at the Steno Dia-
The most widely used descriptions of macromoleculebetes Center using standard techniques [26, 27].
transport across the glomerular capillary wall are basedThe sieving coefficients (u) of Ficoll molecules of dis-
on a hydrodynamic theory of hindered solute transportcrete size were determined after separating molecules
through water-filled, cylindrical pores [28]. Among a va-in urine and serum of the third collection period into
riety of distributions that are commonly used in probabil-narrow fractions by HPLC using Ultrahydrogel 500 and
ity analysis, the one found by curve fitting to best repli-250 columns in series (Waters Corp., Milford, MA, USA)
cate observed values for glomerular sieving of Ficolland a 0.1 mol/L potassium phosphate mobile phase, pH
represents the glomerular capillary wall as a heteropo-6.5, at a flow rate of 0.5 mL/min [21]. The columns were
rous membrane perforated by a lower distribution ofcalibrated with five narrowly dispersed Ficoll fractions
restrictive pores with a log normal size distribution andof known molecular weight supplied by Pharmacia LKB
a parallel upper distribution of shunt-like pores [21]. WeBiotechnology (Uppsala, Sweden). In preparation for
applied this model to the sieving data for both controlthe HPLC separation, the serum samples were diluted
and diabetic groups of subjects. The log normal-plus-1:1 with distilled H2O, and the urine samples were con- shunt model contains three parameters: u, the mean porecentrated threefold using siliconized glass tubes in a
radius; s, a measure of the breadth of the log normalSpeed Vac centrifugal concentrator (Savant Instruments,
distribution (that is, ln s is the natural log of the standardInc., Farmingdale, NY, USA). The samples were then
deviation of the distribution of pore radii about thecentrifuged through 0.2 mm cellulose acetate filters (Rai-
mean); and v0, the shunt parameter, which governs thenin Instrument Co., Woburn, MA, USA) before an ali- fraction of total filtrate volume passing through this non-
quot of 200 mL was injected onto the columns. A fraction restrictive portion of the membrane. In addition to spe-
collector (Model FC203; Gilson Inc., Middleton, WI, cific pore parameters, the membrane barrier to filtration
USA) was used to collect 185 mL fractions of the eluent of water and uncharged Ficoll macromolecules is charac-
during the interval corresponding to retention times of terized by an ultrafiltration coefficient, the product of ef-
26.5 to 38 minutes. The first fraction corresponded to fective hydraulic permeability and total glomerular capil-
molecules of 92 A˚ radius, and the last fraction corre- lary surface area (for two kidneys). The approach that
sponded to molecules of 12 A˚ radius. Each fraction was we used for calculating these intrinsic membrane param-
combined with 3 mL of Cytoscint-ES scintillation fluid eters separates their effects on sieving coefficients from
(ICN Biomedicals, Irvine, CA, USA) and counted for those owing to changes in GFR, renal plasma flow, on-
10 to 20 minutes in a Tri-Carb 4530 scintillation counter cotic pressure, and/or the glomerular transcapillary hy-
(Packard Instrument Co., Downers Grove, IL, USA). draulic pressure difference (DP) [28]. Because DP cannot
Counts per minute (CPM) were used to estimate the be determined in humans, we performed a sensitivity anal-
relative amounts of Ficoll in the fractions. Three frac- ysis using an estimate of the biologically probable range
tions collected from 14 to 15.2 minutes were used as for this value (40 to 50 mm Hg). We found that DP 5
background and subtracted from each subsequent frac- 46 mm Hg minimized the mean squared errors, thus
tion. Two milliliters of eluent immediately following the providing the best fit set of pore parameters for the log
last fraction of interest were collected and counted. The normal 1 shunt model in the control group. Accordingly,
total CPM of the latter and all earlier fractions was com- we used an assumed DP of 46 mm Hg in all subsequent
pared with that of 50 mL aliquots of raw (unseparated) computations of membrane parameters. To allow for a
sample to determine total 3H-labeled Ficoll recovery for possible elevation of DP, we also assumed a second value
each sample. These recoveries were 103 6 12% and 98 6 for DP 5 50 mm Hg in the group with DN.
10% (mean 6 SD) for urine and serum, respectively.
Statistical analysisThe u for each discrete fraction of Ficoll was derived
by dividing the respective urine-to-serum concentration The significance of differences between the DN and
control groups was evaluated by a two-tailed Student’s(that is, CPM ratios) of each fraction by that of inulin.
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Table 1. Variance of urine-to-serum Ficoll ratio
ESR A˚ 16 20 24 28 32 36 40 44 48 52 56 60 62 68
CV % 7.05 8.20 6.51 6.79 7.97 9.99 9.78 9.05 9.64 7.04 6.09 5.65 6.14 9.06
Abbreviations are: ESR, Einstein-Stokes radius; CV, coefficient of variance.
Table 2. Glomerular function
Control Placebo DN Losartan DN
Glomerular filtration rate mL/mina 10467 7967c 8166
Renal plasma flow mL/mina 623658 459621c 441623
Filtration fractiona 0.1760.01 0.1760.01 0.1960.01
Mean arterial blood pressure mm Hg a 8563 10762c 10462d
Plasma oncotic pressure mm Hg a 26.260.5 22.660.4c 23.060.2
Urinary albumin excretion mg/24 hours b 14 (9–26) 964 (599–1660)c 739 (440–1241)d
Urinary IgG excretion mg/24 hoursb 3.5 (2.4–5.2) 52 (22–123)c 41 (23–74)
Urinary IgG4 excretion mg/24 hoursb 0.08 (0.05–0.15) 1.6 (0.3–8.3)c 1.5 (0.4–6.3)
Fractional albumin clearance (1025)b 0.22 (0.13–0.36) 35.4 (17.6–71.3)c 26.7 (14.4–49.4)d
Fractional IgG clearance (1025)b 0.21 (0.15–0.29) 6.7 (2.8–16.1)c 5.3 (2.6–10.6)d
Fractional IgG4 clearance (1025)b 0.14 (0.11–1.17) 11.8 (5.5–25.4)c 9.1 (4.7–17.4)d
a Mean 6 SEM
b Geometric mean (95% CI)
c P , 0.01 vs. Control
d P , 0.05 vs. Placebo
t-test or the Mann–Whitney test, depending on whether trols). Corresponding values of the fractional clearance
the distribution of findings was Gaussian. Differences for albumin, IgG, and IgG4 in early DN exceeded control
within the DN group between the last day of placebo or values by one to three orders of magnitude (P , 0.001;
losartan treatment were analyzed with paired versions Table 2). The mean Ficoll sieving curve in placebo-
of the same two tests. In the former instance, the results treated DN is compared with that in controls in Figure 2.
are expressed as means 6 SEM. Where the distribution As shown, DN is associated with a selective elevation
of findings was skewed, results are expressed as the geo- of u for large nearly impermeant Ficoll molecules in
metric mean 6 log-transformed 95% CI. the 50 to 60 A˚ radius interval. Of note, incremental
enhancement in the u of the largest Ficolls examined
resulted in an increasingly large disparity between theRESULTS
DN and control groups (Fig. 2).Findings in early diabetic nephropathy
Membrane parameters computed from the Ficoll siev-
Glomerular function in the nephropathic diabetic ing curves are summarized in Table 3. Neither the mean
group during placebo therapy is compared with that in radius (u) nor the breadth (s) of the lower distribution
controls in Table 2. Both the GFR (79 6 7 vs. 104 6 of restrictive pores in placebo-treated DN differed from
17) and renal plasma flow rate (459 6 21 vs. 623 6 58
control values. On the other hand, judged by the fraction
mL/mm/1.73 m2) were modestly lower in the DN than the
of filtrate by which they were permeated (v0), the uppercontrol group, with each difference reaching statistical
distribution of shunt-like pores was one order of magni-significance. Mean arterial pressure was higher in DN
tude more prominent in placebo-treated DN than con-than controls, averaging 107 6 2 versus 85 6 6 mm Hg,
trols, a difference that reached statistical significancerespectively (P , 0.05). Conversely corresponding
(P , 0.05; Table 3). The lack of alteration of u and Splasma oncotic pressure was lower, averaging 22.6 6 0.4
and the significant enhancement of v0 were independentversus 26.2 6 0.5 mm Hg, respectively (P , 0.01).
of whether DP was elevated in untreated DN. ElevationAlbumin and IgG excretion rates were uniformly and
of the hypothetical value for DP to 50 from 46 mm Hg,only modestly elevated into a subnephrotic range in the
however, magnified the shunt pathway such that v0 wasDN group, with geometric mean values (and 95% CI)
2.5 6 0.7 3 1024 versus 1.9 6 0.6 3 1024 respectively,of 964 (559 to 1660) and 52 (22 to 123) mg/24 hours,
compared with only 3.6 6 1.5 3 1025 in controls (Table 3).respectively (Table 2). The median excretion rate of IgG4
The magnitude of the fraction of filtrate permeatingin the control population was only a small fraction of
shunt-like pores in untreated DN was related to thecorresponding total IgG, 0.08 (0.05 to 0.15 mg/24 hours).
magnitude of proteinuria. Thus, assuming DP 5 50IgG4 excretion in DN during placebo treatment was ele-
vated to 1.6 (0.3 to 8.3) mg/24 hours (P , 0.01 vs. con- mm Hg, v0 was related by linear regression to the log
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handling. It lowered excretion rates of albumin and IgG
by 21 (P , 0.05) and 17% (P 5 NS) and the correspond-
ing fractional clearances by 23 and 19%, respectively
(P , 0.05; Table 2). The fractional clearance of IgG4,
an anionic subclass of IgG also declined significantly by
23% during losartan therapy (P , 0.05; Table 1).
The administration of losartan to the DN group also
lowered u at the large radius end of the Ficoll sieving
curve toward normal values (Fig. 3); however, only for
molecules of 60 A˚ radius did u of Ficoll during losartan
therapy approach statistical significance (P 5 0.06). In
keeping with the minor changes in Ficoll sieving, losar-
tan-induced alterations in the computed membrane pa-
rameters in DN were modest. They included a trend
toward a lowering of both the mean radius of restrictive
pores (u) and of the fraction of filtrate permeating the
shunt-like pores (v0; Table 3). In the strongly possible
event that vasodepressor therapy with losartan lowered
DP from 50 mm Hg in placebo-treated DN to 46 mm Hg,
the reduction in u would have been from 38.9 6 1.1 to
36.4 6 1.6 (A˚), respectively (P , 0.05). The correspond-
ing reduction in 0 would have been from 2.5 6 0.7 3
1024 to 1.4 6 0.5 3 1024, respectively (P , 0.05; Table 3).
The repair of the size-selective defect during losartan
therapy of DN could have contributed to the observed
Fig. 2. Sieving coefficients (u) of Ficoll are plotted as a function of
reduction in proteinuria.Einstein-Stokes radius (ESR). Symbols are: (s) placebo-treated dia-
betic nephropathy; (n) controls; *P , 0.05.
DISCUSSION
In earlier studies of DN, we used dextran 40, a linear
of both the fractional clearance of albumin (r 5 0.59, polymer of glucopyranose, to characterize the size-selec-
P , 0.05) and IgG (r 5 0.56, P 5 0.06). tive properties of the glomerular barrier. Among patients
with nephrotic range proteinuria, we have consistently
Effects of angiotensin II type 1 receptor blockade observed evidence of impaired size selectivity, as judged
A comparison of some clinical and laboratory findings by selective enhancement of u for large dextrans of
in the diabetic group on the last day of losartan and .50% A˚ [9, 13–15]. In contrast, in DN with lower grades
placebo treatment is provided in Table 4. Neither body of subnephrotic proteinuria, such evidence for impaired
weight nor the rate of urinary sodium excretion were barrier size selectivity has been absent or ambiguous, at
altered during losartan therapy. That losartan blocked best [9, 13–15]. In the present study, we employed Ficoll
the AT1 receptors, however, is indicated by a twofold 70, a polymer of polysucrose, to probe the size-selective
increase in both plasma renin concentration (37 6 6 vs. barrier. Like the dextran 40 used in earlier studies, Ficoll
19 6 2 mU/L, P , 0.01) and plasma Ang II concentration has the requisite properties to be an ideal probe of the
(16 6 3 vs. 8 6 1 pmol/L, P , 0.01; Table 3). Neither size-selective glomerular filtration barrier. These include
the prevailing levels of azotemia (creatinine and BUN) absence of molecular charge, dispersion of component
nor glycemic control as measured by hemoglobin A1c or molecules over a wide and appropriate range of molecu-
fasting blood glucose were influenced by losartan ther- lar sizes, and absence of measurable transport across the
apy, however (Table 3). The effects of losartan on glo- proximal tubule epithelial monolayer [29]. Coinciden-
merular filtration dynamics and renal protein handling tally, the distribution of component molecules in both
in DN are tabulated in Table 2, alongside corresponding dextran 40 and Ficoll 70 is such that each probe permits
findings about placebo therapy. Losartan failed to influ- examination over a 20 to 60 A˚ radius range. Ficoll has
ence GFR, renal plasma flow, or plasma oncotic pressure at least two advantages of dextran that render it a supe-
significantly. Mean arterial pressure, on the other, hand rior and more sensitive probe of the filtration barrier,
was lowered significantly (P , 0.05), albeit only by 3 however. One is greater ease and reproducibility of
mm Hg on average (Table 2). Losartan therapy was assay. In our hands, unlabeled dextran is best separated
by HPLC and assayed by refractive index [14]. The coef-also associated with significant changes in renal protein
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Table 3. Membrane parameters
u v0
DP (mean pore radius) s (fraction of filtrate
mm Hg A˚ (SD about mean) through shunt)
Control 46 39.061.1 1.1860.01 3.661.531025
Placebo DN 46 37.961.2 1.2060.01 1.960.631024a
50 38.961.1b 1.1960.01 2.560.731024a,b
Losartan DN 46 36.461.6 1.2160.02 1.460.531024
50 37.861.2 1.2060.01 1.860.631024
aP , 0.05 vs. Control
bP , 0.05 vs. Losartan at DP 46
Table 4. Effect of angiotensin II receptor blockade
Placebo Losartan P value
Weight kg 7363 7263 NS
UNaV mmol/24 hours 160617 171619 NS
Plasma renin mU/L 1962 3766 ,0.01
Plasma angiotensin II pmol/L 861 1663 ,0.01
Plasma creatinine lmol/L 10368 107610 NS
BUN mmol/L 6.360.6 6.760.7 NS
Hemoglobin Aic % 8.260.2 8.560.3 NS
Fasting blood glucose mmol/L 10.261.6 11.161.8 NS
ficient of variation of the urine-to-serum dextran concen-
tration ratio varies from 7 to 11%, 12 to 16%, and 16 to
19% in the 30 to 40, 42 to 50, and 52 to 60 A˚ radius
interval, respectively. A comparison of the foregoing
coefficients to those reported for 3H-Ficoll in Table 1
reveals that assay for isotopic activity in the latter is far
more reproducible than the refractive index assay for
dextran. A second advantage of Ficoll is that it differs
from loosely coiled dextran in that it has a rigid spherical
configuration [19, 20]. As a result, a Ficoll of a given
chromatographic radius is more restricted during trans-
glomerular permeation than is a dextran of equivalent
in vitro chromatographic radius [21, 22, 29]. Among our
subjects with subnephrotic albuminuria and early DN,
Fig. 3. Sieving coefficients (u) of Ficoll in diabetic nephropathy (DN)
this permitted the clear demonstration of a barrier size are plotted as a function of Einstein-Stokes radius (ESR). Symbols are:
(s) placebo treatment; (X) losartan treatment. (c) P 5 0.06. Data aredefect by virtue of the enhanced sieving of Ficoll mole-
mean 6 SEM.cules in the 50 to 60 A˚ radius range (Fig. 1). Because
dextrans of given radius permeate the glomerular capil-
lary wall more readily than Ficoll of equivalent radius, a
corresponding demonstration of impaired size selectivity reabsorption of the enhanced load of filtered IgG, could
would require examination of glucopyranose molecules account for the aforementioned disparity. It thus seems
.60 A˚, a range that is not measurable because of techni- reasonable to conclude that barrier size defects could
cal considerations and hence was not examined in the account for the level of immunoglobulinuria in DN.
earlier studies [9, 13–15]. Noteworthy in this respect is that blockade of Ang II
Whereas the fractional clearance of IgG in DN was receptors resulted in similar reduction in the fractional
elevated above control by two orders of magnitude, the clearances of IgG, the component molecules of which
corresponding elevation of u for Ficoll of equivalent ra- are mostly neutral or cationic, and of IgG4, a subclass of
dius (56 A˚) was by only approximately 50% (Table 1 IgG, which is strongly anionic (Table 1) [9]. Given a
and Fig. 1). An elevation of the sieving coefficient of reduction in u of 50 to 60 A˚ Ficolls of similar magnitude
IgG comparable to that of Ficoll of 56 A˚ radius, com- during losartan therapy (,20%; Fig. 3), it appears that
Ang II receptor blockade diminishes immunoglobu-bined with the expected large reduction in fractional
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linuria by reducing the density of large, shunt-like pores analysis of Ficoll sieving suggests that also in this in-
stance, the reduction in proteinuria is associated with aand that such pores do not discriminate among IgG mole-
cules of varying charge. diminution in the prominence of shunt-like pores within
the glomerular capillary wall (Fig. 2 and Table 3). TheA comparison between fractional clearances of albu-
min and Ficoll molecules of equivalent chromatographic small magnitude of the change in Ficoll sieving is consis-
tent with the modest reduction that we observed in theradius (36 A˚) fails to reveal a similar relationship in
DN between barrier size selectivity and albuminuria, level of proteinuria and fractional protein clearances.
A larger antiproteinuric effect has been achieved withhowever. For Ficoll 5 36 A˚, the u 5 1021 in controls
(Fig. 1). This exceeds the corresponding fractional clear- higher doses of losartan [abstract; Andersen et al, Diabe-
tologia (in press)] and when AT blockade was combinedance of albumin by five orders of magnitude (2.2 3 1026;
Table 2). Assuming that, as in the rat, 90% of filtered with dietary sodium restriction [34]. We propose that the
use of these perturbations combined with Ficoll sievingalbumin is reabsorbed, we infer that the glomerular siev-
ing coefficient for albumin in humans approximates 1024, could help elucidate the role of improved barrier size
selectivity in the antiproteinuric influence of blockadea value similar to that estimated by micropuncture in
the rat [1–3]. The disparity between u for Ficoll 5 36 A˚ of the renin-angiotensin system. That repair of the size-
and albumin in controls implies that the healthy glomeru- selective barrier by AT1 receptor blockade is likely of
lar barrier restricts albumin on a basis additional to size biological significance is suggested by two recent studies
selectivity, perhaps one that owes to charge selectivity of nondiabetic glomerular disease [35, 36]. In each in-
[10, 30]. An alternative explanation is that the healthy stance, a therapy-induced reduction in proteinuria was
glomerular barrier also exhibits shape selectivity, associated with significant improvement of barrier size-
thereby restricting ellipsoid albumin more than spherical selectivity, as judged by changes in dextran sieving
Ficoll of similar chromatographic radius [21, 22, 29]. [35, 36]. What remains to be elucidated, however, is the
Given that u of Ficoll 5 36 A˚ is not different from role of impairment of charge and shape selectivity in the
control, it seems likely that impairment of either charge genesis of albuminuria and proteinuria in early DN. Also
or shape selectivity, rather than size selectivity, underlies to be resolved is the extent to which Ang II blockade
the observed albuminuria in early DN. Also pointing lowers albuminuria by leading to improvement in these
away from changes in barrier size selectivity in the gene- latter size-independent forms of barrier dysfunction.
sis of modest albuminuria are the observations during
the AT1 receptor blockade. Whereas the fractional clear- ACKNOWLEDGMENTS
ance of albumin declined significantly, there was no cor-
This study was supported by grant DK54600 from the National
responding change in u for Ficoll 5 36 A˚. These findings Institutes of Health and by Medical School Grant (192M026) from
Merck.suggest that the demonstrated loss of barrier size selectiv-
ity in DN has a minor or negligible affect on filtration of
Reprint requests to Bryan D. Myers, M.D., Division of Nephrology,
relatively small macromolecules, such as albumin. Rather, Room S201, 300 Pasteur Drive, Stanford, California 94305-5114, USA.
E-mail: h.takahishi@Ieland.stanford.eduthe shunt-like size defects appear to influence only the
passage of far larger macromolecules, such as IgG.
A decade has now elapsed since we first demonstrated REFERENCES
that an antiproteinuric effect of blockade of the renin- 1. Baldamus CA, Galaske R, Eisenbach GM, Krause HP, Stolte
Ang II system was accompanied by alterations in dextran H: Glomerular protein filtration in normal and nephritic rats. Con-
trib Nephrol 1:37–49, 1975sieving in subjects with early DN. Using a heteroporous
2. Oken DE, Kirschbaum BB, Landwehr DM: Micropuncture stud-membrane model, we interpreted our findings to indicate ies of the mechanisms of normal and pathologic albuminuria. Con-
that the Ang II blockade had eliminated a small popula- trib Nephrol 24:1–7, 1981
3. Tojo A, Endou H: Intrarenal handling of proteins in rats usingtion of large, protein-permeable pores from the glomeru-
fractional micropuncture technique. Am J Physiol 263(4 Pt 2):lar barrier of our nephropathic subjects [31]. Similar F601–F606, 1992
findings were later reported and conclusions drawn by 4. Tucker BJ, Rasch R, Blantz RC: Glomerular filtration and tubu-
lar reabsorption of albumin in preproteinuric and proteinuric dia-Remuzzi et al, who essentially duplicated our findings
betic rats. J Clin Invest 92:686–694, 1993in a more advanced stage of DN [32]. In each study,
5. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M: Glomer-
the improved barrier size selectivity induced by Ang II ular size- and charge-selectivity in insulin-dependent diabetes mel-
litus. Kidney Int 33:100–106, 1988blockade was achieved by therapy with an angiotensin-
6. Di Mario U, Morano MD, Cancelli A, Bacci S, Frontoni S,converting enzyme (ACE) inhibitor, a class of antihyper-
Pietravalle P, Gambardella S, Andreani D: New parameters
tensive agent that had been shown to consistently limit to monitor the progression of diabetic nephropathy. Am J Kidney
Dis 13:45–48, 1989the rate of protein trafficking across the glomerular capil-
7. Ghiggeri BM, Candiano G, Delfino G, Queirolo C: Electricallary wall [33]. In the present study, we have shown that
charge of serum and urinary albumin in normal and diabetic hu-
a similar antiproteinuric effect can be achieved in early mans. Kidney Int 28:168–177, 1985
8. Kverneland AB, Feldt-Rasmussen B, Vidal P, Welinder B,DN when AT1 receptors are blocked (Table 2). Our
Andersen et al: Glomerular permselectivity 2137
Bent-Hansen L, Soegaard U, Decker T: Evidence of changes in extraction and the estimation of plasma flow in the diseased human
kidney. Am J Physiol 30:F726–F733, 1991renal charge-selectivity in patients with type I (insulin- dependent)
diabetes mellitus. Diabetologia 29:634–639, 1986 24. Canaan-Kuhl S, Venkatraman ES, Ernst SIB, Olshen RA, My-
ers BD: Relationships among protein and albumin concentrations9. Nakamura Y, Myers BD: Charge-selectivity of proteinuria in dia-
betic glomerulopathy. Diabetes 37:1202–1211, 1988 and oncotic pressure in nephrotic plasma. Am J Physiol 264(6 Pt
2):F1052–F1059, 199310. Deen WM, Satvat V: Determinants of the glomerular filtration
of proteins. Am J Physiol 241:F162–F170, 1981 25. Jensen JS, Borch-Johnsen K, Deckert T, Deckert M, Jensen
G, Feldt-Rasmussen B: Reduced glomerular size- and charge-11. Christensen EL, Carone FA, Rennke HG: Effect of molecular
charge on endocytic uptake of ferritin in renal proximal tubule selectivity in clinically healthy individuals with microalbuminuria.
Eur J Clin Invest 25:608–614, 1995cells. Lab Invest 44:351–358, 1981
12. Christensen EL, Rennke HG, Carone FA: Renal tubular uptake 26. Kappelgaard AM, Nielsen MD, Giese J: Measurement of angio-
tensin-II in human plasma: Technical modifications and practicalof protein: Effect of molecular charge. Am J Physiol 244:F436–
F441, 1983 experience. Clin Chim Acta 67:299–306, 1976
27. Millar JA, Leckie BJ, Morton JJ, Jordan J, Tree M: A micro13. Myers BD: Pathophysiology of proteinuria in diabetic glomerular
disease. J Hypertens 8(Suppl 1):S41–S46, 1990 assay for active and total renin concentration in human plasma
based on antibody trapping. Clin Chim Acta 101:5–15, 198014. Myers BD, Nelson RG, Blouch K, Bennett PH, Knowler WC,
Ming T, Beck G, Mitch WE: Progression of overt nephropathy 28. Deen WM, Bridges CR, Brenner BM, Myers BD: Heteroporous
model of glomerular size selectivity: Application to normal andin non-insulin-dependent diabetes. Kidney Int 47:1781–1789, 1995
15. Scandling JD, Myers BD: Glomerular size-selectivity and mi- nephrotic humans. Am J Physiol 249(3 Pt 2):F374–F389, 1985
29. Bohrer MP, Deen WM, Robertson CR, Troy JL, Brenner BM:croalbuminuria in early diabetic glomerular disease. Kidney Int
41:840–846, 1992 Influences of molecular configuration on the passage of macromol-
ecules across the glomerular capillary wall. J Gen Physiol 74:583–16. Ala-Houbali I, Pasternack A: Fractional dextran and protein
clearances in glomerulonephritis and in diabetic nephropathy. Clin 593, 1979
30. Guasch A, Deen WM, Myers BD: Charge-selectivity of the glo-Sci (Lond) 72:289–296, 1987
17. Ruggenenti P, Mosconi L, Sangalli F, Casiraghi F, Gambara merular filtration barrier in healthy and nephrotic humans. J Clin
Invest 92:2274–2282, 1993V, Remuzzi, G, Remuzzi A: Glomerular size-selectivity dysfunc-
tion in NIDDM is not ameliorated by ACE-inhibition or by calcium 31. Morelli E, Loon N, Meyer T, Peters W, Myer BD: Effect of
converting enzyme inhibition on barrier function in diabetic glo-channel blocker. Kidney Int 55:984–994, 1999
18. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Ma- merulopathy. Diabetes 39:76–82, 1990
32. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Re-zerska M, Battaglia C, Bertani T, Remuzzi G: Short- and long-
term effect of angiotensin II receptor blockade in rats with experi- muzzi G: Effect of low-dose enalapril on glomerular size-selectivity
in human diabetic nephropathy. J Nephrol 6:36–43, 1993mental diabetes. J Am Soc Nephrol 4:40–49, 1993
19. Bohrer MP, Patterson GD, Carroll PJ: Hindered diffusion of 33. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of
antihypertensive therapy on the kidney in patients with diabetes:dextran and Ficoll in microporous membranes. Macromolecules
17:1170–1173, 1984 A meta-regression analysis. Ann Intern Med 118:129–138, 1993
34. Gansevoot RT, de Zeeuw D, de Jong PE: Is the antiproteinuric20. Davidson MG, Deen WM: Hindered diffusion of water-soluble
macromolecules in membranes. Macromolecules 21:3474–3481, effect of ACE inhibition mediated by interference in the renin-
angiotensin system. Kidney Int 45:861–867, 19941988
21. Blouch K, Deen WM, Fauvel JP, Bialek J, Derby G, Myers 35. Plum J, Bunten B, Nemeth R, Grabensee B: Effects of the angio-
tensin II antagonist valsartan blood pressure, proteinuria, and renalBD: Molecular configuration and glomerular size-selectivity in
healthy and nephrotic humans. Am J Physiol 273(3 Pt 2):F430– hemodynamics in patients with chronic renal failure and hyperten-
sion. J Am Soc Nephrol 9:2223–2234, 1998F437, 1997
22. Oliver JD, Anderson, S, Troy JL, Brenner BM, Deen WM: 36. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M,
Ruggenenti P, Remuzzi G: ACE-inhibition and ANG II receptorDetermination of glomerular size-selectivity in the normal rat with
Ficoll. J Am Soc Nephrol 3:214–228, 1992 blockade improve glomerular size-selectivity in IgA nephropathy.
Am J Physiol 276(3 Pt 2):F457–F466, 199923. Battilana C, Zhang H, Olshen RA, Wexler L, Myers BD: PAH
